Cellectis SA/ FR0010425595 /
2024-05-03 5:35:14 PM | Chg. +0.160 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | High | Low |
---|---|---|---|---|---|---|
2.760EUR | +6.15% | 237,739 Turnover: 649,053.445 |
2.700Bid Size: 550 | 2.780Ask Size: 500 | 2.790 | 2.620 |
GlobeNewswire
04-26
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire
04-22
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...
GlobeNewswire
04-10
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...
GlobeNewswire
04-08
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and...
GlobeNewswire
03-14
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updat...
GlobeNewswire
01-16
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agre...
GlobeNewswire
01-04
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro D...
GlobeNewswire
01-04
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, ...
GlobeNewswire
2023-12-22
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
GlobeNewswire
2023-12-09
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-6...
GlobeNewswire
2023-12-05
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actio...
GlobeNewswire
2023-11-15
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
GlobeNewswire
2023-11-06
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
GlobeNewswire
2023-11-03
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Target...
GlobeNewswire
2023-11-03
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies a...
GlobeNewswire
2023-11-02
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I ...
GlobeNewswire
2023-11-02
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
GlobeNewswire
2023-11-02
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Soci...
GlobeNewswire
2023-11-01
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
GlobeNewswire
2023-11-01
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca